Genmab — December 2019
-
we were just recently hinting at more trials in this field - New small trial: Desensitization in Kidney Allograft Using Daratumumab (DARDAR) https://clinicaltrials.gov/ct2/show/NCT04204980?term=daratumumab+OR+ofatumumab+OR+tisotumab+OR+Genmab+OR+arzerra+OR+duobody&lupd_s=12%2F18%2F2019&draw=2&rank=2
-
1 more : Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma - https://clinicaltrials.gov/ct2/show/NCT04205240?term=daratumumab+OR+ofatumumab+OR+tisotumab+OR+Genmab+OR+arzerra+OR+duobody&lupd_s=12%2F18%2F2019&draw=2&rank=5
-
GEN1042 with BioNtech started recruiting https://clinicaltrials.gov/ct2/history/NCT04083599?A=1&B=2&C=merged#StudyPageTop
-
CureVac's mRNA platform lyder da ret spændende. Det ser ud til, at de kan bygge mRNA sequences i stabil form. Det burde så både kunne bruges til aktivere immunforsvaret "naturligt" mod cancer celler, få cancercellerne til at udstille flere targets (f.eks. mere CD38) eller at tagge cancer celler med et target, der ikke findes andre steder i kroppen, så bivirkninger mindskes.
-
probably a fair statement , also given this earlier comment - “The achievement of starting a Phase I/IIa clinical trial with a product candidate developed in only four years is a validation of our highly productive partnership with Genmab,” said Prof. Ugur Sahin, CEO of BioNTech - RE timing
-
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind